Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 2023

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 10
Chunk 2023
---
,534,254
     
    819

    Chia-Lin Simmons
     
    3,532,834
     
    2,239

There
were 415,239 broker non-votes with respect to each such nominee for the first proposal.

Proposal
2 – The amendment to the Company’s 2023 Equity Incentive Plan to increase the number of shares authorized
for issuance thereunder was approved by the Company’s stockholders. The final voting results were as follows:

    For
     
    Against
     
    Abstain

    3,527,889
     
    4,985
     
    2,199

There
were 415,239 broker non-votes with respect to the second proposal.

Proposal
3 – The proposal to waive the limit on the number of shares of Common Stock that may be issued to certain shareholders
pursuant to that certain Securities Purchase Agreement, dated July 24, 2024, and that certain Common Stock Purchase Agreement,
dated July 26, 2024, as required by NYSE American, was approved by the Company’s stockholders. The final voting results
were as follows:

    For
     
    Against
     
    Abstain

    3,126,104
     
    406,770
     
    2,199

There
were 415,239 broker non-votes with respect to the third proposal.

Proposal
4 – The reincorporation of the Company in Nevada and simultaneous name change to “Channel Therapeutics Corporation”
was approved by the Company’s stockholders. The final voting results were as follows:

    For
     
    Against
     
    Abstain

    2,603,047
     
    2,335
     
    929,691

There
were 415,239 broker non-votes with respect to the fourth proposal.

Proposal
5 – The appointment of Marcum LLP as the independent registered public accounting firm of the Company for the fiscal
year ending December 31, 2024 was ratified by the Company’s stockholders. The final voting results were as follows:

    For
     
    Against
     
    Abstain

    3,941,195
     
    6,918
     
    2,199

Role
of our Board of Directors in Risk Oversight

One
of the